Stay updated with breaking news from Database Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo plus Yervoy experienced a 28% reduction in the risk of death vs. sunitinib at eight years from the...
Expert oncologists who treat patients with advanced RCC discuss updates from clinical trials presented during the 2023 European Society for Medical Oncology Congress that further defined the treatment paradigm in advanced RCC and gave a peek into the potential future of the disease management.
First and only hypoxia-inducible factor-2 alpha inhibitor approved for these adult patients with advanced RCC This approval of WELIREG marks the first time a new treatment has been approved in a...
The FDA has approved belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC) following a PD-1 or PD-L1 inhibitor and a VEGF TKI.
The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.